Epizyme files for a $69 million IPO
Epizyme, a biotech developing therapeutics for patients with
genetically defined cancers, filed on Thursday with the SEC to
raise up to $69 million in an initial public offering. The
company recently entered into a collaboration agreement with
Abbott Laboratories to develop a diagnostic to detect which
patients would qualify for Epizyme's product candidates.
The Cambridge, MA-based company, which was founded in 2007 and booked $45 million in collaboration revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on 3/22/2013. Primary backers include New Enterprise Associates (25.1% pre-IPO stake), Kleiner, Perkins, Caufield & Byers (20.1%), Bay City Capital (15.5%), Celgene European Investment Company (14.5%) and MPM Capital (12.8%). Citi, Cowen & Company, and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.